Literature DB >> 22429163

Remodeling of ventricular repolarization in a chronic doxorubicin cardiotoxicity rat model.

Sergey Kharin1, Valeria Krandycheva, Alena Tsvetkova, Marina Strelkova, Dmitry Shmakov.   

Abstract

Doxorubicin, one of the most effective anticancer drugs, is characterized by severe cardiotoxic effects, which induce cardiac remodeling and congestive heart failure. The aim of the study was to evaluate remodeling of ventricular repolarization heterogeneity in chronic doxorubicin cardiotoxicity in rats. Doxorubicin cardiotoxicity was produced by six equal intraperitoneal injections of the drug in a cumulative dose of 15 mg/kg in a 2-week period. Electrophysiological mapping of the ventricular epicardium in situ was performed 6 weeks after the last injection of doxorubicin. Activation-recovery intervals (ARIs) were used for the evaluation of the heterogeneity in repolarization durations. The major findings were as follows: (1) ARIs on the ventricular epicardium of both ventricles were significantly prolonged in the doxorubicin group and (2) this inhomogeneous prolongation of ARIs on the ventricular epicardium resulted in (i) the increase in the dispersion of repolarization across the ventricular epicardium and (ii) the inhomogeneous alterations of the regional ARI gradients on the ventricular epicardium. These changes in repolarization could explain the electrocardiographic alterations, that is, the prolongation of the QT interval and flattening of the T wave.
© 2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429163     DOI: 10.1111/j.1472-8206.2012.01037.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

1.  Resiniferatoxin reduces cardiac sympathetic nerve activation to exert a cardioprotective effect during myocardial infarction.

Authors:  Ludefu Su; Yu Liu; Yanhong Tang; Mingmin Zhou; Liang Xiong; Congxin Huang
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

2.  Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology.

Authors:  Mykola Ya Spivak; Rostyslav V Bubnov; Ilya M Yemets; Liudmyla M Lazarenko; Natalia O Tymoshok; Zoia R Ulberg
Journal:  EPMA J       Date:  2013-07-29       Impact factor: 6.543

3.  Suppression of hERG K+ current and cardiac action potential prolongation by 4-hydroxynonenal via dual mechanisms.

Authors:  Seong Woo Choi; Si Won Choi; Young Keul Jeon; Sung-Hwan Moon; Yin-Hua Zhang; Sung Joon Kim
Journal:  Redox Biol       Date:  2018-08-24       Impact factor: 11.799

4.  Weighted gene co-expression network-based approach to identify key genes associated with anthracycline-induced cardiotoxicity and construction of miRNA-transcription factor-gene regulatory network.

Authors:  Guoxing Wan; Peinan Chen; Xue Sun; Xiaojun Cai; Xiongjie Yu; Xianhe Wang; Fengjun Cao
Journal:  Mol Med       Date:  2021-11-03       Impact factor: 6.354

5.  Fuzi and Banxia Combination, Eighteen Antagonisms in Chinese Medicine, Aggravates Adriamycin-Induced Cardiomyopathy Associated with PKA/β2AR-Gs Signaling.

Authors:  Fengjiao Sun; Yingying Huang; Lili Li; Chao Yang; Pengwei Zhuang; Yanjun Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-03       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.